Clinical Trial Update: Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta [Phase 2]

View source ↗

Summary

Long-term extension phase 2 study of Setrusumab in adults with Osteogenesis Imperfecta (types I, III, IV) was terminated, and results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteogenesis Imperfecta

Drugs mentioned

• Setrusumab (setrusumab)

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Osteogenesis Imperfecta | Phase 2 | Status: TERMINATED | Results posted: 2025-07-23